Cipla Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Cipla de 11.5% y 8.5% por año respectivamente. Se prevé que el BPA crezca en un 11.6% al año. Se espera que la rentabilidad financiera sea de 14.1% en 3 años.

Información clave

8.4%

Tasa de crecimiento de los beneficios

8.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.1%
Tasa de crecimiento de los ingresos	8.5%
Rentabilidad financiera futura	14.3%
Cobertura de analistas	Good
Última actualización	15 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14

Recent updates

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

May 21

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 30

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Mar 23

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Dec 18

Calculating The Fair Value Of Cipla Limited (NSE:CIPLA)

Dec 05

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Oct 27

If You Like EPS Growth Then Check Out Cipla (NSE:CIPLA) Before It's Too Late

Sep 16

Cipla Limited (NSE:CIPLA) Shares Could Be 23% Above Their Intrinsic Value Estimate

Aug 31

It's Unlikely That Cipla Limited's (NSE:CIPLA) CEO Will See A Huge Pay Rise This Year

Aug 18

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Jul 12

Previsiones de crecimiento de beneficios e ingresos

NSEI:CIPLA - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	327,361	51,320	41,158	58,510	12
3/31/2026	305,831	50,700	41,462	52,500	29
3/31/2025	280,118	46,450	33,207	48,184	27
3/31/2024	254,466	41,216	27,846	41,339	N/A
12/31/2023	251,163	37,082	N/A	N/A	N/A
9/30/2023	243,407	34,532	25,988	37,924	N/A
6/30/2023	235,108	31,112	N/A	N/A	N/A
3/31/2023	225,593	28,019	20,736	32,377	N/A
12/31/2022	222,187	26,383	N/A	N/A	N/A
9/30/2022	218,874	25,660	20,120	29,160	N/A
6/30/2022	216,105	24,884	N/A	N/A	N/A
3/31/2022	217,078	25,168	26,285	33,259	N/A
12/31/2021	210,718	25,681	N/A	N/A	N/A
9/30/2021	207,616	25,876	28,362	37,113	N/A
6/30/2021	202,801	25,417	N/A	N/A	N/A
3/31/2021	191,205	24,049	29,418	37,552	N/A
12/31/2020	188,779	22,374	N/A	N/A	N/A
9/30/2020	180,802	18,403	23,627	31,968	N/A
6/30/2020	174,377	16,462	N/A	N/A	N/A
3/31/2020	170,805	15,465	20,684	30,685	N/A
12/31/2019	171,206	16,678	N/A	N/A	N/A
9/30/2019	167,572	16,489	18,294	25,720	N/A
6/30/2019	163,733	15,546	N/A	N/A	N/A
3/31/2019	163,232	15,277	11,640	16,911	N/A
12/31/2018	155,224	13,391	N/A	N/A	N/A
9/30/2018	154,287	14,074	N/A	N/A	N/A
6/30/2018	154,992	14,530	N/A	N/A	N/A
3/31/2018	151,053	14,105	6,466	14,628	N/A
12/31/2017	147,618	11,701	N/A	N/A	N/A
9/30/2017	144,951	11,444	N/A	N/A	N/A
6/30/2017	141,637	10,762	N/A	N/A	N/A
3/31/2017	143,340	10,064	N/A	23,818	N/A
12/31/2016	142,509	11,213	N/A	N/A	N/A
9/30/2016	137,547	10,071	N/A	N/A	N/A
6/30/2016	134,335	12,219	N/A	N/A	N/A
3/31/2016	135,480	13,600	N/A	17,408	N/A
12/31/2015	135,044	16,847	N/A	N/A	N/A
9/30/2015	131,633	16,694	N/A	N/A	N/A
6/30/2015	124,782	15,368	N/A	N/A	N/A
3/31/2015	113,454	11,808	N/A	11,734	N/A
12/31/2014	106,195	11,818	N/A	N/A	N/A
9/30/2014	105,627	11,383	N/A	N/A	N/A
6/30/2014	104,164	11,976	N/A	N/A	N/A
3/31/2014	101,734	13,884	N/A	15,633	N/A
12/31/2013	94,330	14,042	N/A	N/A	N/A
9/30/2013	89,509	14,602	N/A	N/A	N/A
6/30/2013	86,548	15,901	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (11.5% al año) de CIPLA es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (11.5% al año) de CIPLA crezcan menos que el mercado Indian (17.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de CIPLA crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (8.5% al año) de CIPLA crezcan más despacio que el mercado de Indian (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8.5% al año) de CIPLA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CIPLA sea baja dentro de 3 años (14.1%).

Cipla Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Price target increased by 8.7% to ₹1,391

Price target increased to ₹1,208

Price target increased to ₹1,202

Consensus forecasts updated

Recent updates

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Dividend increased to ₹13.00

Cipla Limited, Annual General Meeting, Aug 20, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Price target increased by 8.7% to ₹1,391

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Is Cipla (NSE:CIPLA) A Risky Investment?

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Price target increased to ₹1,208

Price target increased to ₹1,202

Second quarter 2023 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Cipla Limited Announces Executive Changes

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹8.51 (vs ₹8.86 in 1Q 2022)

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022

Cipla Limited Notifies That the United States Food and Drug Administration Conducted A Pre Approval Inspection

If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Cipla Limited (NSEI:CIPLA) agreed to acquire unknown stake in GoApptiv Private Limited.

Cipla Limited (NSEI:CIPLA) entered into a definitive agreement to acquire an unknown minority stake in Achira Labs Pvt. Ltd

The South African Health Products Regulatory Authority Approves Sweet-Tasting, Heat-Stable, 4-In-1 Fixed-Dose Combination of Four Antiretroviral Treatments Developed by Cipla and DNDi